UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | October 21, 2024 4:00 P.M. |
Form: | S-3 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | October 21, 2024 4:00 P.M. |
Form: | S-3 | ||||||
|
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/24/2024 | $8.50 | Buy | Ascendiant Capital Markets |
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients WHITE BEAR LAKE, Minnesota, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces that its Investigational Device Exemption (IDE) application for its pivotal study of the Acclaim® Fully Implanted Cochlear Implant has been approved by the U.S. Food and Drug Administration (FDA). The Acclaim® technology includes an implanted sensor designed to leverage the natural anatomy of the ear to capture sound, making it different from
Twelve Members of the Independence Through Enhancement of Medicare and Medicaid (ITEM) Coalition Sign Letter to CMS Seeking Clarification of Prior Decision Making and Action to Bring Novel Hearing Technology to Medicare Beneficiaries WHITE BEAR LAKE, Minnesota, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, expresses gratitude to the Independence Through Enhancement of Medicare and Medicaid ("ITEM") Coalition and the twelve ITEM member signatories for sending a strong letter to CMS supporting a reconsideration of the benefit category for fully implanted active middle ear he
WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event: LD Micro Main Event XVII Presentation Date: Tuesday, October 29, 2024 Time: 12:00 PM Pacific Time Register
4 - Envoy Medical, Inc. (0001840877) (Issuer)
EFFECT - Envoy Medical, Inc. (0001840877) (Filer)
DEFA14A - Envoy Medical, Inc. (0001840877) (Filer)
DEF 14A - Envoy Medical, Inc. (0001840877) (Filer)
Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year WHITE BEAR LAKE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the second quarter ended June 30, 2024. "We are pleased with the steady progress that Envoy Medical has made this quarter and year-to-date in advancing our goal of becoming a leading cochle
The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its "breakthrough" fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the first quarter ended March 31, 2024. Financial and Corporate Highlights from Q1 2024 All three participants in the ongoing Early Feasibility Study (EFS) at Mayo Clinic (Rochester, MN) have completed their 12-m
Company Provides Corporate Update that Include Updates on its Investigational Fully Implanted Acclaim® Cochlear Implant Meeting its Early Feasibility Study Milestones Recent bipartisan Congressional bill, the Hearing Device Coverage Clarification Act, seeks to open a pathway to insurance coverage for the Company's Esteem® Fully Implanted Active Middle Ear Implant WHITE BEAR LAKE, Minn., April 02, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2023. Financial and
Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50
WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently
Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company
Ascendiant Capital analyst Edward Woo initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Price Target of $8.5.